Versant Venture Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Versant Venture Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,092,152	Closed	-$44.4M	–	6
2016 Q1	$44.4M	Hold	1,092,152	–	–	32.04%	2
2015 Q4	$45.3M	Hold	1,092,152	–	–	26.52%	2
2015 Q3	$16.8M	Hold	1,092,152	–	–	9.64%	4
2015 Q2	$27.1M	Hold	1,092,152	–	–	34.41%	2
2015 Q1	$25M	Hold	1,092,152	–	–	21.95%	2
2014 Q4	$29.5M	Buy	+1,092,152	New	+$18.8M	28.2%	2

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Versant Venture Management's FPRX Position: Q2 2016 in Review

Versant Venture Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2016, closing a stake of 1,092,152 shares — an estimated $44.4M sold.

Versant Venture Management first reported a position in FPRX in Q4 2014 and held it in 6 quarters. The position peaked at $45.3M in Q4 2015. 170 funds tracked by Wall St. Rank hold FPRX as of Q2 2016.

Versant Venture Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Versant Venture Management sold 1,092,152 Five Prime Therapeutics, Inc. shares in Q2 2016, an estimated $44.4M.
Versant Venture Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 6 quarters.
Versant Venture Management's Five Prime Therapeutics, Inc. position peaked at $45.3M in Q4 2015.
170 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2016.

Based on Versant Venture Management's 13F filing for Q2 2016, filed 28 Jul 2016.